Top-line results show semaglutide for weight loss (Wegovy) cut cardiovascular events in the 17,000-person SELECT CV outcomes trial, which should reframe the health benefit of this weight loss drug.
A new study says that fructose, a ubiquitous sugar in the western diet, prevents the brain from recognizing fullness, promoting overeating and weight gain.